http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022514262-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2019-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022514262-A |
| titleOfInvention | Twin Immune Cell Engager |
| abstract | A twin-type immune cell engager (TWICE) is a kit or composition for treating cancer, which comprises a first component and a second component. Each component contains a target-directed moiety that binds to a tumor antigen expressed by cancer or an antigen expressed by non-cancer cells in the tumor microenvironment. In some embodiments, the first and second components are an immune cell-binding domain that can exert an immune cell-binding effect when bound to an immune cell-binding domain within the other component, and the other component, respectively. Includes a complementary binding domain that can bind to a complementary antigen when bound to a complementary binding domain within. In some embodiments, the first and / or second component comprises a complementary functional domain that is active when directed to the cancer cell or its microenvironment. The TWICE complex of the present invention provides a unique ability to combine multiple functions into a two-component complex that is activated in the tumor microenvironment. Accordingly, the complex of the invention is meaningful in having a single approach of administering a two-component complex that is localized in the tumor microenvironment and has the ability to generate two different signals to benefit the patient. Brings some advantages. This unique structure offers advantages not found in prior art structures. [Selection diagram] FIG. 1A |
| priorityDate | 2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1761.